Danderyds Sjukhus AB
Danderyd, Sweden
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on people undergoing diagnostic or therapeutic Adenoma removal during colonoscopy, a procedure that looks inside the large intestine to find and treat abnormal growths. The sedation method being tested uses a patient‑controlled system that delivers the drug propofol through a vein (intravenous) to keep the person comfortable and relaxed. This is compared with the standard sedation that uses the drugs alfentanil and midazolam, also given intravenously. The main goal is to see whether the patient‑controlled approach leads to higher satisfaction with the experience.
Participants will receive the assigned sedation during their colonoscopy and will be asked to complete a short questionnaire after the procedure to report how satisfied they felt. The study will also record how much medication was used, how long the procedure and recovery lasted, and any side effects or problems that occur. After the colonoscopy, participants will be monitored until they are fully awake and able to go home, and the overall success of completing the procedure will be noted.
The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.
5 criteria
7 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Danderyd, Sweden
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is the medication being tested in this study. It is given through an IV line either as a quick injection or as a continuous drip. In the trial, patients can control the amount they receive while they are having an endoscopic procedure. The purpose is to see if letting patients adjust their own propofol sedation makes them feel more satisfied with the experience compared with the usual sedation methods.
is one of the standard drugs used for comparison in the study. It is also given by IV injection. Alfentanil is a short‑acting pain reliever that helps keep patients comfortable and reduces pain during the endoscopic procedure. The trial uses it as a typical sedation option to compare against the patient‑controlled propofol approach.
is another commonly used sedative that serves as a comparator in this trial. It is administered intravenously and works by calming patients and causing mild sleepiness, making the endoscopic procedure easier to tolerate. The study includes midazolam to represent the usual sedation practice against which the new patient‑controlled propofol method is evaluated.
Administered as an intravenous bolus or continuous infusion, propofol is a short‑acting anesthetic that is approved and widely used for induction and maintenance of general anesthesia and for procedural sedation. It works by enhancing the activity of the brain’s GABA‑A receptors, which slows nerve signals and produces a rapid loss of consciousness. In medical literature it is well‑studied, with many clinical trials confirming its safety and effectiveness for sedation during endoscopic procedures. Pharmacologically it is classified as a short‑acting intravenous anesthetic agent.
Given by intravenous injection, alfentanil is an approved synthetic opioid used for short‑duration analgesia and sedation during surgery or diagnostic procedures. It binds to mu‑opioid receptors in the nervous system, reducing the perception of pain and producing a calm state. The drug is well documented in the medical literature as a fast‑acting opioid with a brief effect, making it useful for brief procedures. It belongs to the pharmacological class of short‑acting synthetic opioid analgesics.
Midazolam is administered intravenously for rapid onset of sedation, anxiety relief, and memory loss during medical procedures. It is an approved benzodiazepine that enhances GABA‑A receptor activity, increasing inhibitory signals in the brain to produce calmness and drowsiness. Extensive clinical use and research support its safety and effectiveness for procedural sedation and pre‑operative anxiety. It is classified as a short‑acting benzodiazepine sedative.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.